MARKET

CELGZ

CELGZ

Celgene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4827
+0.0024
+0.50%
Closed 16:00 11/13 EST
OPEN
0.4800
PREV CLOSE
0.4803
HIGH
0.4900
LOW
0.4800
VOLUME
3.19K
TURNOVER
--
52 WEEK HIGH
1.650
52 WEEK LOW
0.3500
MARKET CAP
343.39M
P/E (TTM)
0.0602
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CELGZ and other stocks commission-free!

Open a Webull account and fund it to get a free stock

CELGZ News

  • Editas adds to Celgene collaboration-stoked up move, shares ahead 4%
  • Seeking Alpha - Article.20h ago
  • Editas Expands Its Celgene Partnership After Another Strong Quarter
  • MotleyFool.com.22h ago
  • Geron: Hold Despite Slim Premium As Promising Trials Await Funding
  • Seeking Alpha - Article.1d ago
  • Celgene inks second collaboration deal with Skyhawk
  • Seeking Alpha - Article.1d ago

More

Industry

Pharmaceuticals
+0.07%
Pharmaceuticals & Medical Research
+0.16%

Hot Stocks

Name
Price
%Change

About CELGZ

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.
More

Webull offers Celgene Corporation (CELGZ) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.